18m
Hosted on MSNWhat To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide BattleCompounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales ...
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The blistering rally in Hims & Hers Health Inc. that’s captivated meme-stock traders has ground to a halt, setting up a ...
It appears some investors may be coming round to the thinking of Ken Griffin, the billionaire founder of hedge fund Citadel, who recently warned that the "uncertainty and chaos" created by President ...
On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.
Brand collaborations remain a popular tactic for challenger brands to reach new audiences. Bubble Skincare and Touchland will ...
Domino's Pizza -- one of the best performing stocks of the last two decades -- headlines Monday's slate of earnings. Hims & Hers Health -- [whose shares tumbled Friday after Novo Nordisk said a shorta ...
10h
Hosted on MSNHims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop On Semaglutide UpdateHims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results